Zhang XF, Liu PY, Zhang SJ, Zhao KL, Zhao WX. Principle and progress of radical treatment for locally advanced esophageal squamous cell carcinoma. World J Clin Cases 2022; 10(35): 12804-12811 [PMID: 36569017 DOI: 10.12998/wjcc.v10.i35.12804]
Corresponding Author of This Article
Wei-Xin Zhao, MD, Department of Radiation Oncology, Fudan University Shanghai Cancer Center, No. 270 Dongan Road, Xuhui, Shanghai 200032, China. zwx_zhxf@163.com
Research Domain of This Article
Oncology
Article-Type of This Article
Evidence Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Xiao-Fei Zhang, Kuai-Le Zhao, Wei-Xin Zhao, Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China
Xiao-Fei Zhang, Kuai-Le Zhao, Wei-Xin Zhao, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
Xiao-Fei Zhang, Kuai-Le Zhao, Wei-Xin Zhao, Shanghai Clinical Research Center for Radiation Oncology Shanghai Key Laboratory of Radiation Oncology, Shanghai 200032, China
Pei-Yi Liu, Department of Orthopedics, Tongren Hospital, School of Medicine Shanghai Jiao Tong University, Shanghai 200336, China
Shu-Juan Zhang, Department of Oncology, The Second People's Hospital of Kashgar, Kashgar 844000, Xinjiang Uygur Autonomous Region, China
Author contributions: Zhang XF, Liu PY and Zhang SJ contribute equally; Zhao KL and Zhao WX substantial contributions to the conception and design of the study; Zhang XF and Liu PY draft the article or revising it critically for important intellectual content, acquisition of the data and analysis and interpretation of the data; Zhang SJ approved the final version to be published.
Supported byKey Clinical Specialty Project of Shanghai.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Wei-Xin Zhao, MD, Department of Radiation Oncology, Fudan University Shanghai Cancer Center, No. 270 Dongan Road, Xuhui, Shanghai 200032, China. zwx_zhxf@163.com
Received: August 1, 2022 Peer-review started: August 1, 2022 First decision: September 5, 2022 Revised: September 19, 2022 Accepted: November 10, 2022 Article in press: November 10, 2022 Published online: December 16, 2022 Processing time: 135 Days and 5.7 Hours
Abstract
Esophageal squamous cell carcinoma is one of the most common malignant tumors in the digestive system in China and the world. Most patients are diagnosed as locally advanced or advanced stage. Concurrent chemoradiotherapy is the standard treatment for locally advanced esophageal squamous cell carcinoma. This study intends to summarize the evidence-based medical evidence of the treatment principle of locally advanced esophageal squamous cell carcinoma, the selection of radiotherapy dose, the outline of radiotherapy target and the selection of chemotherapy scheme. As a result, the effect of radiotherapy and chemotherapy is equivalent to that of surgery for the radical treatment of esophageal squamous cell carcinoma. In the era of immunization, it is recommended to use involved field irradiation. Fluorouracil plus cisplatin regimen is the standard chemotherapy regimen. FOLFOX regimen and paclitaxel plus fluorouracil regimen are optional concurrent chemotherapy regimens. The toxic and side effects of different chemotherapy regimens are different, which can be selected according to the actual situation of patients.
Core Tip: For the radical treatment of esophageal squamous cell carcinoma, the effect of radiotherapy and chemotherapy is equivalent to that of surgery. In the era of immunization, it is recommended to use involved field irradiation. Fluorouracil plus cisplatin regimen is the standard chemotherapy regimen, FOLFOX regimen and paclitaxel plus fluorouracil regimen are optional concurrent chemotherapy regimens. The toxic and side effects of different chemotherapy regimens are very different, which can be selected according to the actual situation of patients.
